118 Avenue , 14315
Suite 140
Edmonton, AB T5L 4S6
Canada
250 744 2487
https://www.auriniapharma.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 300
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Mr. Peter S. Greenleaf M.B.A. | President, CEO & Director | 1,46M | N/A | 1970 |
Mr. Joseph M. Miller C.P.A. | Chief Financial Officer | 819,89k | N/A | 1974 |
Mr. Matthew Maxwell Donley M.B.A. | Executive Vice President of Operations & Strategy | 837,21k | N/A | 1969 |
Mr. Stephen P. Robertson | Executive VP, General Counsel, Corporate Secretary & Chief Compliance Officer | 776,44k | N/A | 1982 |
Andrea Levin Christopher | Head of the Corporate Communications & Investor Relations | N/A | N/A | N/A |
Mr. Fran Lynch | Vice President of Sales | N/A | N/A | N/A |
Mr. Michael R. Martin | Chief Business Officer | 325,45k | N/A | 1972 |
Ms. Sue Evans | Senior Vice President of Global Regulatory Affairs | N/A | N/A | N/A |
Mr. Scott Habig | Chief Commercial Officer | N/A | N/A | 1960 |
Ms. DeDe Sheel | Vice President of Investor Relation | N/A | N/A | N/A |
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Aurinia Pharmaceuticals Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 7. Die grundlegenden Scores sind Audit: 8, Vorstand: 5, Shareholderrechte: 2, Kompensation: 10.